Innovative contraceptive approaches with estetrol: a review of mammalogical safety data
Malignant and benign mammary gland diseases (MG) are leading causes of female oncological and hormone-dependent pathology. The mammalogical safety of combined hormonal contraceptives (CHCs) remains under debate, underscoring the need for regimens that minimally affect MG tissue proliferation and breast cancer (BC) risk...